GlassScriptPhysician profile
James W Mcdowell
NPI 1255370482
$1,859.87
in general payments reported to CMS, 2019-2025
29 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $134 · 2021: $337 · 2022: $153 · 2023: $217 · 2024: $239 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.12 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.36 | 2021-2025 | |
| Amgen INC. | $196.23 | 2019-2024 | Prolia, Evenity |
| Dexcom, INC. | $146.21 | 2021-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $135.17 | 2023-2025 | Rexulti |
| Pfizer INC. | $113.93 | 2019-2025 | |
| Novo Nordisk INC | $110.20 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $85.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $73.56 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $62.36 | 2019-2022 | |
| Abbott Laboratories | $62.02 | 2022-2024 | Proclaim, Freestyle Libre 3 |
| Amarin Pharma, INC. | $55.22 | 2019-2021 | |
| Astellas Pharma US INC | $51.85 | 2019-2024 | Veozah |
| Acadia Pharmaceuticals INC | $50.92 | 2023-2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $50.14 | 2019-2021 | |
| Organogenesis INC. | $45.83 | 2019-2023 | Puraply |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $43.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.53 | 2019 | |
| Daiichi Sankyo INC. | $33.42 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $32.07 | 2020-2024 | Breztri |
| Xeris Pharmaceuticals, INC. | $23.25 | 2023 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $19.63 | 2025 | |
| Grifols USA, LLC | $18.82 | 2019 | |
| Merck Sharp & Dohme LLC | $18.06 | 2024 | Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $16.77 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $16.49 | 2021 | |
| Integra Lifesciences Corporation | $16.15 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Allergan, INC. | $15.63 | 2019 | |
| Lilly USA, LLC | $13.30 | 2019 | |
| Glaxosmithkline, LLC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.